Summary
Eli Lilly and Company (LLY) filed an 8-K on October 20, 2011, to report its financial results for the third quarter and the first nine months of 2011. The filing includes a press release detailing these results, as well as a teleconference for analysts and media to discuss the performance. Notably, the company is providing non-GAAP financial measures alongside GAAP results to offer a clearer view of ongoing operations, excluding items like restructuring charges, in-process R&D expenses, and the impact of U.S. healthcare reform. Investors are encouraged to review these non-GAAP figures, as they are used by management for performance evaluation and resource allocation, and provide a basis for more meaningful period-over-period comparisons. The press release also contains financial expectations for the full year 2011, including GAAP and non-GAAP earnings per share guidance. The information furnished in this 8-K, particularly Item 2.02 and its accompanying press release, is intended to provide investors with insights into the company's financial condition and operational trends.
Key Highlights
- 1Announcement of Q3 and year-to-date 2011 financial results via press release and analyst teleconference.
- 2Company is presenting both GAAP and non-GAAP financial measures, including net income and earnings per share.
- 3Non-GAAP results exclude significant items such as restructuring charges and in-process R&D costs.
- 4Restructuring charges are primarily related to workforce reductions and cost structure initiatives.
- 5In-process R&D charges are associated with collaborations, specifically with Boehringer Ingelheim (diabetes) and an in-licensing transaction with Acrux.
- 6The impact of foreign exchange rate changes and U.S. healthcare reform on results is quantified.
- 7Financial expectations for the full year 2011 are provided, including both GAAP and non-GAAP EPS guidance.